Goldman Sachs analyst Asad Haider maintained a Hold rating on Pfizer yesterday and set a price target of $26.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asad Haider has given his Hold rating due to a combination of factors reflecting both Pfizer’s strengths and competitive pressures. He views the company’s new pneumococcal vaccine data and the move toward a higher-valent next-generation candidate as evidence of a serious effort to defend its long-standing position in this market, even as rivals advance their own products in adult and pediatric segments.
At the same time, his valuation framework, which applies a 9.0x multiple to forward adjusted EPS and yields an unchanged $26 price target, suggests limited upside from current levels. While he acknowledges potential benefits from cost-saving initiatives, a milder-than-expected Medicare Part D impact, and possible positive surprises from the oncology pipeline, these opportunities are balanced by ongoing competitive risks and forecast declines in Prevnar revenues over the coming decade.
According to TipRanks, Haider is a 4-star analyst with an average return of 16.0% and a 66.67% success rate. Haider covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Pfizer, and Merck & Company.
In another report released on May 8, Berenberg Bank also maintained a Hold rating on the stock with a $25.00 price target.